By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share, data seen by Reuters shows. The data from advertising tracking firm MediaRadar, ‌which has not been previously reported, shows Novo spent an estimated$316 million advertising its weight-los ...